The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Ajua, Anthony ^a   Lell, Bertrand ^a,b   Agnandji, Selidji Todagbe ^b   Asante, Kwaku Poku ^c   Owusu Agyei, Seth ^c,d   Mwangoka, Grace ^e   Mpina, Maxmilliam ^e   Salim, Nahya ^e   Tanner, Marcel ^e,f   Abdulla, Salim ^e   Vekemans, Johan ^g   Jongert, Erik ^g   Lievens, Marc ^g   Cambron, Pierre ^g   Ockenhouse, Chris F ^h   Kremsner, Peter G ^a,b   Mordmüller, Benjamin ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CERMEL Centre de Recherche Médicale de Lambaréné   (Gabon)

^c KINTAMPO HEALTH RESEARCH CENTRE   (Ghana)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e IFAKARA HEALTH INSTITUTE   (Tanzania)

^f SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^g GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^h PATH Malaria Vaccine Initiative   (United States)

Author keywords

Antibody; Avidity; Correlate of protection; Malaria; Plasmodium falciparum; RTS; S; Vaccine

Indexed keywords

AS01E ADJUVANT; CIRCUMSPOROZOITE PROTEIN; CIRCUMSPOROZOITE PROTEIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; PROTEIN ANTIBODY; RTS,S SPOROZOITE VACCINE; SPOROZOITE VACCINE; UNCLASSIFIED DRUG; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; PROTOZOAL PROTEIN;

ADJUVANT THERAPY; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PARASITE IMMUNITY; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; RISK REDUCTION; SPOROZOITE; VACCINATION; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; KAPLAN MEIER METHOD; MALARIA, FALCIPARUM; RANDOMIZED CONTROLLED TRIAL;

ANTIBODY AFFINITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION SCHEDULE; KAPLAN-MEIER ESTIMATE; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 84928660014     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0605-7     Document Type: Article

References (18)

1. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo B G NO, Kabwende AL, et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367:2284-95.
2. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365:1863-75.
3. RTS, S Clinical Trials Partnership. Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11:e1001685.
4. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, et al. Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis. 2011;11:102-9.
5. Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, et al. Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011;11:741-9.
6. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, et al. Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet. 2007;370:1543-51.
7. Egan JE, Weber JL, Ballou WR, Hollingdale MR, Majarian WR, Gordon DM, et al. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science. 1987;236:453-6.
8. Porter MD, Nicki J, Pool CD, Debot M, Illam RM, Brando C, et al. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint. Clin Vaccine Immunol. 2013;20:803-10.
9. Fairley H. Chemotherapeutic suppression and prophylaxis in malaria. Trans R Soc Trop Med Hyg. 1945;38:311-55.
10. Reed RC, Louis-Wileman V, Wells RL, Verheul AF, Hunter RL, Lal AA. Re-investigation of the circumsporozoite protein-based induction of sterile immunity against Plasmodium berghei infection. Vaccine. 1996;14:828-36.
11. Rickman LS, Gordon DM, Wistar Jr R, Krzych U, Gross M, Hollingdale MR, et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet. 1991;337:998-1001.
12. Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R, et al. Evaluation of the safety and immunogenicity of the RTS, S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis. 2010;202:1076-87.
13. Clement F, Dewar V, Van Braeckel E, Desombere I, Dewerchin M, Swysen C, et al. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum. Malar J. 2012;11:384.
14. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg. 1991;45:297-308.
15. Busse CE, Czogiel I, Braun P, Arndt PF, Wardemann H. Single-cell based high-throughput sequencing of full-length immunoglobulin heavy and light chain genes. Eur J Immunol. 2014;44:597-603.
16. Muellenbeck MF, Ueberheide B, Amulic B, Epp A, Fenyo D, Busse CE, et al. Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med. 2013;210:389-99.
17. Bachmann MF, Kalinke U, Althage A, Freer G, Burkhart C, Roost H, et al. The role of antibody concentration and avidity in antiviral protection. Science. 1997;276:2024-7.
18. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation Group. N Engl J Med. 1997;336:86-91.